Electromed, Inc. Announces Clinical Abstract Poster at ATS Conference: Bronchiectasis Patients Showed Improved Outcomes and Reduction in Healthcare Resource Utilization When Using HFCWO Therapy
May 19 2022 - 9:00AM
Business Wire
Electromed, Inc. (NYSE American: ELMD) today announced the
results of a third-party, clinical study presented as a clinical
abstract poster at the American Thoracic Society International
Conference in San Francisco, CA. The study’s key findings reveal
that patients who used high frequency chest wall oscillation
(“HFCWO”) therapy experienced an improvement in health outcomes, as
well as a reduction in healthcare resource utilization (“HCRU”),
including a reduction in medication usage.
An independent retrospective cohort analysis was conducted on
patients with non-cystic fibrosis bronchiectasis patients (“NCFBE”)
who received HFCWO therapy using IQVIA’s PharMetrics Plus® for
MedTech, one of the largest US health plan databases of adjudicated
integrated medical and pharmacy claims. The study aimed to
understand patient characteristics and compare HCRU and outcomes
(both before and after receipt of HFCWO) among NCFBE patients, in a
large administrative claims database representative of the US
commercially-insured population (including Medicare Advantage).
“We are pleased to further the body of evidence in support of
HFCWO therapy and SmartVest, continuously showing improved patient
outcomes, including a reduction in hospitalizations,” commented
Kathleen Skarvan, President and Chief Executive Officer of
Electromed. “These important findings further our mission and
commitment to helping patients breathe easier and live better.”
Bronchiectasis is an irreversible, chronic lung condition
characterized by enlarged and permanently damaged bronchi. The
condition is associated with recurrent lower respiratory
infections, inflammation, reduction in pulmonary function, impaired
respiratory secretion clearance, increased hospitalizations and
medication use, and increased morbidity and mortality.1,2,3
The SmartVest system uses HFCWO, a clinically proven therapy
that helps clear the lungs of excess secretions, thereby reducing
the risk of respiratory infections and hospitalizations. HFCWO
delivers alternating pulses of air into a vest garment that rapidly
compresses and releases the chest wall, resulting in an oscillation
in airflow within the airways that acts to loosen, thin, and propel
mucus toward the major airways where it can be expectorated.
About Electromed, Inc.
Electromed manufactures, markets, and sells products that
provide airway clearance therapy, including the SmartVest® Airway
Clearance System, to patients with compromised pulmonary function.
It is headquartered in New Prague, Minnesota and founded in 1992.
Further information about Electromed can be found at
www.smartvest.com.
______________________
1 King PT et al. COPD.
2005;2(1):27-34.
2 Alzeer AH et al. BMC Pulm Med. 2007;
7:17.
3 Seitz AE et al. Chest.
2010;138(4):944-949.
EM00630.2022-05
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220519005013/en/
Kathleen Skarvan President and Chief Executive Officer
kskarvan@electromed.com 952-758-9299
Electromed (AMEX:ELMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Electromed (AMEX:ELMD)
Historical Stock Chart
From Apr 2023 to Apr 2024